title: The androgen receptor transcriptional program in castration-resistant prostate cancer: cell lines vs. tissue samples.
abstract: The androgen receptor (AR) is central to the initiation and progression of prostate cancer, even after castration. Its transcriptional activity has previously been studied in cell lines. A group at the University of Cambridge recently outlined the AR transcriptional program in tissue samples, with an emphasis on castration-resistant tumors. AR binding sites, gene-expression changes (in xenografts), and potential transcription factor interactions were notably different from those observed in cultured cells. These discrepancies suggest a distinct signaling network for the AR in vivo and serve as a reminder that results from in vitro models should be checked against clinical realities.
authors.affiliation: Clinical Pharmacology Program; Office of the Clinical Director; National Cancer Institute; Bethesda, MD USA.
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Roth
authors.affiliation: Clinical Pharmacology Program; Office of the Clinical Director; National Cancer Institute; Bethesda, MD USA.
authors.forename: Cody J
authors.initials: CJ
authors.lastname: Peer
authors.affiliation: Clinical Pharmacology Program; Office of the Clinical Director; National Cancer Institute; Bethesda, MD USA.
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Price
authors.affiliation: Clinical Pharmacology Program; Office of the Clinical Director; National Cancer Institute; Bethesda, MD USA.
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
mesh_terms: D000818:Animals; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000235:genetics*; D011944:Receptors, Androgen / Q000502:physiology*
chemical_list: D011944:Receptors, Androgen
keywords: androgen receptor; binding site; castration-resistant prostate cancer; transcription factor; transcriptional program